Clinical Trial Update: DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 DETERMINE trial treatment arm 05 is evaluating the combination of vemurafenib and cobimetinib in adults with BRAF-positive cancers; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Colorectal Cancer
• Erdheim-chester Disease
• Glioma
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Papillary Thyroid Carcinoma

Drugs mentioned

• Cotellic (cobimetinib)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Cancer Research UK | Conditions: Haematological Malignancy, Melanoma | Phase 2, Phase 3 | Status: RECRUITING